An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

Table 1 Technical feasibility and efficiency of correlative sample analysis efficiency by histology and biopsy site^a,b

TOTAL N = 129			total # of cell recovered, mean (range) × 10⁶	# of cores, mean (range)	# of cells per core, mean (range) × 10⁶
DATA BY BIOPSY SITE
liver	Core	N = 36	0.876 (0.057–8.78)	4.42 (2–8)	0.194 (0.016–1.46)
liver	Exn	N = 2	1.76 (1.28–2.25)
LN	Core	N = 29	1.00 (0.049–4.07)	3.66 (1–6)	0.293 (0.024–1.36)
LN	Exn	N = 1	10.8
skin	Core	N = 9	1.19 (0.011–6.70)	4.78 (3–11)	0.349 (0.004–2.23)
skin	Exn	N = 7	1.46 (0.021–3.35)
lung	Core	N = 10	1.22 (0.001–6.50)	5.00 (3–8)	0.276 (0.002–1.63)
lung	Exn	N = 1	0.073
other^b	Core	N = 33	0.49 (0.012–1.65)	4.21 (1–8)	0.121 (0.002–0.40)
other^b	Exn	N = 1	14.4
DATA BY HISTOLOGY
SCCHN	Core	N = 10	1.92 (0.009–8.78)	3.90 (1–6)	0.42 (0.002–1.63)
SCCHN	FNA	N = 1	0.07
TNBC	Core	N = 13	0.57 (0.027–1.87)	4.54 (2–8)	0.151 (0.007–0.62)
TNBC	Exn	N = 2	0.99 (0.035–1.95)
HGSC	Core	N = 33	0.72 (0.013–4.07)	3.94 (1–8)	0.211 (0.003–1.36)
HGSC	Exn	N = 1	14.4
MM	Core	N = 12	0.54 (0.012–1.13)	4.42 (1–8)	0.120 (0.002–0.28)
MM	Exn	N = 4	1.58 (0.021–3.35)
MST	Core	N = 49	0.87 (0.011–6.70)	4.41 (2–11)	0.220 (0.004–2.23)
MST	Exn	N = 4	4.05 (1.28–10.8)

^asix samples excluded due to technical errors between May 1, 2017 and June 1, 2017
^bmost common sites included peritoneal mass (12), abdominal wall (5), chest wall (3), omentum (3), others (11)
Exn Excision, FNA fine needle aspirate, LN lymph node